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7,8-Dihydro-8-oxoguanine (8-oxoG) is the most common form of
oxidative DNA damage in human cells. Biochemical studies have
shown that 8-oxoG decreases the DNA cleavage activity of human
topoisomerase I, an enzyme vital to DNA metabolism and stability.
We present the 3.1-Å crystal structure of human topoisomerase I in
noncovalent complex with a DNA oligonucleotide containing 8-oxoG
at the 1 position in the scissile strand. We find that 8-oxoG reor-
ganizes the active site of human topoisomerase I into an inactive
conformation relative to the structures of topoisomerase I–DNA
complexes elucidated previously. The catalytic Tyr-723–Phe rotates
away from the DNA cleavage site and packs into the body of the
molecule. A second active-site residue, Arg-590, becomes disordered
and is not observed in the structure. The docked, inactive conforma-
tion of Tyr-723–Phe is reminiscent of the related tyrosine recombinase
family of integrases and recombinases, suggesting a common regu-
latory mechanism. We propose that human topoisomerase I binds to
DNA first in an inactive conformation and then rearranges its active
site for catalysis. 8-OxoG appears to impact topoisomerase I by
stabilizing the inactive, DNA-bound state.
The most common type of oxidative damage identified inmammalian cells is 7,8-dihydro-8-oxoguanine (8-oxoG), with
roughly 100,000 8-oxoG lesions formed per rat cell per day (1).
DNA polymerases incorporate adenine bases opposite 8-oxoG,
generating G:C3 T:A transversion mutations, the second most
common somatic mutation in human cancer. 8-OxoG:C base
pairs are repaired by elaborate defense systems in nearly all
organisms. In humans, the 8-oxoguanine DNA glycosylase en-
zyme (hOGG1; ref. 2) catalyzes the excision of the 8-oxoG base
from a duplex and cleavage of the DNA backbone. hOGG1
recognizes 8-oxoG by forming a hydrogen bond between the
protonated N7 atom in the damaged base and a main-chain
carbonyl on the enzyme. The analogous enzyme in bacteria,
MutM, is structurally unrelated to hOGG1 (3) and was shown to
make base-specific contacts with the ‘‘estranged’’ base opposite
the lesion (4). The impact of 8-oxoG lesions on DNA topoisom-
erases, enzymes necessary for the relaxation of DNA superheli-
cal tension throughout the genome, is not expected to result from
the specific recognition of damaged sites, but rather from
random contacts made between such enzymes that act genome-
wide and sites of DNA damage.
Human topoisomerase I is vital for most cellular processes
involving DNA, including replication, transcription, and recom-
bination, and it is the sole target of the camptothecin anticancer
drugs (5). Human topoisomerase I breaks one strand of duplex
DNA and relaxes superhelical tension by a postulated ‘‘con-
trolled rotation’’ mechanism (6). The 765-aa enzyme is com-
posed of four major regions: a highly charged and putatively
unstructured N-terminal domain (residues 1–200; removed for
structural studies), a conserved core domain (residues 201–635),
a flexible linker domain (residues 636–712), and a conserved
C-terminal domain (residues 713–765) that contains the catalytic
Tyr-723 residue (7). Several crystal structures of human topo-
isomerase I in both covalent and noncovalent complexes with
DNA have been reported (6, 8–10). These structures revealed
that the core domain is composed of CAP (residues 202–434)
and CAT (residues 435–635) regions that wrap completely
around the DNA duplex, positioning the active site around the
scissile phosphate group. The active site contains the catalytic
tyrosine (Tyr-723), two arginines (Arg-488, Arg-590), one his-
tidine (His-632), and one lysine (Lys-532) (6, 8, 10).
The CAT region of human topoisomerase I is structurally
similar to the tyrosine recombinase family of DNA integrases
and recombinases from bacteria and phage (8). These recom-
binases and integrases also use an active site made up of a
tyrosine, two arginines, a histidine (or tryptophan), and a lysine
(8, 11–14). In the crystal structures of human topoisomerase
I-DNA complexes (6, 8–10), the catalytic tyrosine (or inactive
phenylalanine in noncovalent complexes) is positioned adjacent
to the scissile DNA phosphate group, ready for catalysis. In the
tyrosine recombinase family, however, the catalytic tyrosine has
been observed docked up to 27 Å away from the remaining
active-site residues (13). This alternative positioning of the
active-site nucleophile has been interpreted as a regulatory
mechanism used by these enzymes to prevent catalysis until the
DNA substrate binds properly to the enzyme (13).
Several types of DNA damage impact the catalytic activity of
human topoisomerase I (15). In particular, 8-oxoG lesions at the 1
position (just downstream) relative to the site of cleavage distinctly
affect the action of human topoisomerase I (16). Single-turnover
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Table 1. Crystallographic refinement statistics
Resolution, Å (highest shell) 20–3.14 (3.19–3.14)
Space group P21
Unit cell dimensions a  57.2, b  122.5, c  72.0,   97.4°
No. of total reflections 38,120
No. of unique reflections 17,165
Mean redundancy 2.22
Rsym, % (highest shell) 5.9 (30.0)
Completeness, % (highest shell) 95.6 (90.5)




Bond length, Å 0.00821
Bond angles, degree 1.41
Dihedral angles, degree 21.5
Improper angles, degree 1.02
No. of protein atoms 4,457
Mean B value, protein atoms, Å2 59.0
No. of DNA atoms 896
Mean B value, DNA atoms, Å2 45.3
No. of solvent atoms 26
Mean B value, solvent atoms, Å2 27.5
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DNA cleavage assays with suicide substrates revealed that strand
cleavage activity by human topoisomerase I is decreased in the
presence of an 8-oxoG lesion whereas topoisomerase I binding to
DNA is enhanced (16). To unravel the structural basis of the impact
of 8-oxoG on human topoisomerase I, we determined the crystal
structure of a noncovalent complex of the enzyme with a 22-bp
DNA oligonucleotide containing an 8-oxoG base at the 1 position
on the scissile strand. We find the active site Tyr-723–Phe residue
is docked into the interior of the protein, 7.4 Å away from the
scissile phosphate group. This positioning of the catalytic residue is
reminiscent of the inactive conformations of the tyrosine recom-
binases and integrases and may represent a central intermediate on
the path toward DNA cleavage and relaxation by human topoisom-
erase I.
Materials and Methods
Protein Purification and DNA Oligonucleotides. N-terminally trun-
cated human topoisomerase I (70 kDa, residues 175–765) con-
taining a Tyr-723–Phe mutation was expressed by using bacu-
lovirus in Spodoptera frugiperda (Sf9) insect cells (7). The
inactive Tyr-723–Phe mutant form of the enzyme was used to
produce a noncovalent complex with DNA. Single-stranded
DNA oligonucleotides were purchased in reverse-phase HPLC
purity from Oligos Etc. (Midlands, TX) and annealed as de-
scribed (6) to create the following 22-bp DNA duplex (16):
10 5 1 1 5 12
5-AAAAAGACTT∧ oGGAAAAATTTTT-3 scissile
3-TTTTTCTGAA CCTTTTTAAAAA-5 intact,
where ∧ indicates the weakly preferred cleavage site (17), and the
bold oG indicates the position of the 8-oxoG base. This sequence
has proven useful for previous studies of human topoisomerase
I (6–10, 18–22).
Crystallization and Data Collection. Crystals of N-terminally trun-
cated Tyr-723–Phe mutant form of human topoisomerase I in
noncovalent complex with duplex DNA were grown by sitting drop
Fig. 1. Crystal structure of human topoisomerase I in complex with DNA
containing an 8-oxoG lesion. Superimposed (using 544 C atoms) in gray is the
structure of human topoisomerase I in complex with nondamaged DNA
(Protein Data Bank ID code 1A36; ref. 6) The DNA duplexes from three other
human topoisomerase I structures are also shown.
Fig. 2. (A) Human topoisomerase I active-site residues in the 8-oxoG structure with the 8-oxoG base (8OG) shown. Superimposed in transparent gray is the
Protein Data Bank ID code 1A36 structure (6). (B) Stereoview of the active site of the 8-oxoG structure in the same orientation as A, showing 3.1-Å resolution
2Fobs  Fcalc electron density (contoured at 1).
Table 2. rms and distance deviations between the 8-oxoG
structure and the structure of the 70-kDa form of human
topoisomerase I in noncovalent complex with DNA
Deviation Residue(s) rmsddistance, Å
rmsd
All nonsolvent atoms 1.7
All protein atoms 1.8
CAP protein atoms 202–434 1.8
CAT protein atoms 435–633 1.3
Linker protein atoms 641–712 3.1
C-term protein atoms 713–765 1.4
All DNA atoms 0.87
P positions 0.86
Distance





rmsd, rms deviation. Protein Data Bank ID code 1A36 (6).








vapor diffusion at 22°C as described (6). Crystals were cryopro-
tected at 22°C in crystallant containing 20% ethylene glycol before
flash-cooling in liquid nitrogen and belong to space group P21 with
one protein–DNA complex in the asymmetric unit. Diffraction data
were collected at 100 K at Brookhaven National Laboratory,
Upton, NY (beamline X12B) from a single crystal and were
processed and reduced by using DENZO and SCALEPACK (23).
Structure Determination and Refinement. The structure was deter-
mined by molecular replacement (AMORE; ref. 24) using the
structure of a human topoisomerase I in complex with DNA as
a search model (Protein Data Bank ID code 1A36) (6). Model
adjustments were performed by using O, and the structure was
refined by using torsion angle dynamics in CNS (25). Residues
202–633 and 641–765 of the enzyme and all 22 bp of the DNA
duplex are present in the final model. The 8-oxoG base and the
novel positioning of the active site Tyr-723–Phe residue were
placed by using composite annealed omit maps. The Tyr-723–
Phe residue exhibits thermal displacement parameters of 63 Å2,
similar to that exhibited by the protein region of the structure
(Table 1). Late in refinement, bulk solvent and overall aniso-
tropic B-factor corrections were added, as well as 26 well-
ordered waters. The final model exhibits good geometry (Table
1) and no Ramachandran outliers (26). Figures were generated
with MOLSCRIPT (28), RASTER3D (29), and BOBSCRIPT (27).
Results
Overall Structure. The crystal structure of a 70-kDa form of
human topoisomerase I in noncovalent complex with a 22-bp
duplex DNA oligonucleotide containing 8-oxoG at the 1
position on the scissile strand (the 8-oxoG structure) was refined
to 3.1 Å and crystallographic R and cross-validating Rfree values
of 0.258 and 0.300, respectively (Table 1). While this structure of
topoisomerase I is in complex with a site of DNA damage, it is
similar overall to the human topoisomerase I–DNA complexes
reported previously (Fig. 1, Table 2) (6, 9, 10). Maximum shifts
between protein domains of 1.3 Å for the CAP, 3.0 Å for the
linker domain, and 3.6 Å for the C-terminal domain are observed
between the 8-oxoG structure and the complex of human
topoisomerase I with nondamaged DNA (Fig. 1). These values
are within the limits of flexibility described for human topo-
isomerase I protein–DNA complexes (9).
The 8-oxoG base in this structure was built into clear electron
density at the 1 position in the scissile strand by using
composite annealed omit maps. A small number of changes are
observed in the overall protein–DNA contacts in the 8-oxoG
structure relative to previous topoisomerase I-DNA complexes
(7–10): interactions between DNA phosphates and His-367,
Lys-374, Thr-411, Ala-489, and Asn-491 are lost, but new
interactions are formed with Gln-578 and Lys-493. Each change
is at least 15 Å from the 8-oxoG base and thus are likely to reflect
simple variability in enzyme–DNA contacts and not structural
distortions caused by the DNA lesion. The O8 atom on the
8-oxoG base forms no polar or nonpolar contacts with the
protein. The closest protein side chain is Asn-722, which places
its N2 atom 3.9 Å from O8 on the 8-oxoG base. We find that
the Asn-722 side chain can be modeled such that its N2 atom
is 3.4 Å from the O8 atom. Thus, during the DNA binding phase
of catalysis, Asn-722 could form a hydrogen bond with the
8-oxoG base. The Asn-722 residue does not make this interaction
in our current structure, however. Instead, its N2 atom is
involved in a 3.2-Å hydrogen bond with the main-chain carbonyl
oxygen of Thr-718.
Impact of 8-OxoG on the Topoisomerase I Active Site. Although the
overall structure of the 8-oxoG complex is similar to previous
topoisomerase I–DNA structures, the active-site region deviates
significantly. When CAT regions of the 8-oxoG structure and the
structure of topoisomerase I in complex with nondamaged DNA
(6) are superimposed, several shifts in the active site of the 8-oxoG
structure are evident (Fig. 2, Table 2). Moderate changes in
side-chain positions (1.2–1.3 Å) occur for the active-site residues
Arg-488, Lys-532, and His-632. The catalytic Tyr-723–Phe, how-
ever, undergoes a rotamer shift (described in detail below) and the
Arg-590 side chain becomes disordered and is not observed.
Arg-590 helps to neutralize the charge on the scissile DNA phos-
phate group, likely facilitating nucleophilic attack by the catalytic
Tyr-723 residue (6, 10). These observations suggest that the posi-
Fig. 3. (A) Catalytic Tyr-723–Phe residue before (white; from Protein Data Bank
ID code 1A36) and after (red) repositioning, with composite annealed omit Fobs 
Fcalc density (3.1-Å resolution). (B) The buried Tyr-723-Phe in the 8-oxoG structure.
The tyrosyl hydroxyl, if it were present, could form two hydrogen bonds (with
Val-626 and Ser-719, if this residue were modeled in the preferred rotamer
position shown).
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tioning of the Tyr-723 side chain adjacent to the scissile phosphate
is required for proper Arg-590 ordering at the active site.
The Tyr-723–Phe side chain in the 8-oxoG structure undergoes
a 7.4-Å shift in position relative to previous structures and packs by
using a preferred rotamer into a novel cavity within the body of the
enzyme (Table 2; Fig. 3). Difference density in composite annealed
Fobs  Fcalc omit maps, as well as density in initial 2Fobs  Fcalc maps,
provided clear evidence for placement of this side chain in its new
conformation (Fig. 3A). Tyr-723–Phe in this orientation packs well
within a novel cavity formed between the CAT and C-terminal
domains and makes van der Waals contacts with several residues,
including Ala-594, Thr-718, Ser-719, and Leu-724 (Fig. 3B). As a
tyrosine, this side chain could also form two hydrogen bonds within
this pocket. First, a 2.8-Å hydrogen bond could form between the
phenolic oxygen of the tyrosine and the main-chain carbonyl oxygen
of Val-626. Second, if the side chain of Ser-719 is shifted by 120° to
a favored rotamer, its hydroxyl oxygen is 2.2 Å from the phenolic
oxygen of Tyr-723. Both Val-626 and Ser-719 are completely
conserved in the type IB topoisomerases of known sequence (30).
Thus, given small structural shifts to accommodate the tyrosyl
hydroxyl group, it is likely that the catalytic side chain of human
topoisomerase I can pack into the interior of the enzyme and be
stabilized by hydrogen bonds. This structure is distinct from the
topoisomerase I–DNA complexes determined to date; in all pre-
vious structures, the Tyr-723–Phe residue is positioned ready for
catalysis (e.g., Fig. 2A).
Creating the Tyr-723–Phe Binding Pocket. The CAT region and
C-terminal domain of human topoisomerase I undergo subtle,
but important, structural changes to create a binding pocket in
the interior of the enzyme (Fig. 4A). The largest alterations
occur in helices 16, 17 from the CAT, and 21 from the
C-terminal domain. Thr-597 and Leu-602 in 16 shift by 2.4 and
1.5 Å (C-C), respectively; Val-626, Leu-629 and Cys-630 in
17 shift by 2.2, 1.8, and 1.7 Å, respectively; and Trp-732 in 21
Fig. 4. (A) Stereoview of changes required to form the interior binding pocket for Tyr-723–Phe (green, active; magenta, inactive). The 8-oxoG structure is in
red and blue (1 8-oxoG:C base pair in yellow), and the Protein Data Bank ID code 1A36 structure (and A:T base pair) is in gray (6). (B) Stereoview of the
superposition of the 8-oxoG structure (yellow) on that of -integrase (green; 171 equivalent C positions, rms deviation  3.6 Å) revealing the shift in the catalytic
residues for each structure.








shifts by 1.9 Å. The combined effect of these concerted shifts is
to create the binding pocket for the Tyr-723–Phe side chain (Fig.
4A). The presence of the O8 atom on the 8-oxoG base appears
to facilitate these conformational shifts. If the CAT and C-
terminal regions of topoisomerase I remained unchanged, the
CG atom of Thr-718 would clash sterically with the O8 atom (at
2.9 Å; Fig. 4A). In the 8-oxoG structure, however, the position
of Thr-718 has shifted by 2.6 Å, safely distancing itself from the
8-oxoG base (now 4.3 Å away). The electron density is clear for
this positioning and rotamer orientation of Thr-718, and we find
that it cannot be modeled to form a hydrogen bond with the O8
atom on the 8-oxoG base.
The related tyrosine recombinase family of bacterial and
phage integrases and recombinases has also been found to dock
its catalytic tyrosines away from its remaining active-site residues
(11–14). The -integrase places its catalytic residue 17.9 Å from
the active site (Tyr-342 CZ—Arg-212 CZ), compared with 11.2
Å for this human topoisomerase I structure (Tyr-723-Phe CZ—
Arg-488 CZ) (ref. 13; Fig. 4B). Such docked orientations are
likely to represent inactive conformations used to limit catalytic
activity until suitable substrates are bound. Other members of
the tyrosine recombinase family dock their catalytic tyrosines
away from their active sites at a range of distances: Flp recom-
binase at 27.2 Å, bacteriophage HP1 integrase at 11.2 Å, and
XerD recombinase at 10.2 Å (Tyr CZ–Arg CZ) (11, 12, 14). It
is expected that both human topoisomerase I and the tyrosine
recombinases would have to reorganize their active sites to
generate active conformations for catalysis. The use of a docked,
inactive tyrosine conformation may represent a common regu-
latory mechanism for both type IB topoisomerases and tyrosine
recombinases.
Discussion
We have shown a crystal structure of a DNA topoisomerase in
the presence of a site of DNA damage. The structure reveals a
unique conformation at the human topoisomerase I active site:
the catalytic Tyr-723–Phe residue in this noncovalent complex is
rotated 64° away from the scissile phosphate and is docked into
an interior binding pocket (Figs. 3B and 4A). In addition, the side
chain of Arg-590 is disordered (Fig. 2 A), suggesting that when
the catalytic Tyr-723–Phe residue is rotated away this adjacent
active-site residue cannot adopt a stable conformation. The
tyrosine recombinase family of bacterial phage integrases and
recombinases also positions its catalytic tyrosines up to 27 Å
away from its remaining active-site residues (11–14). These
enzymes share a similar structure, active site, and catalytic
mechanism of single-stranded DNA cleavage with the eukary-
otic type I topoisomerases (7–10). Thus, the positioning of a
catalytic tyrosine away from the active site may be a common
mechanism used by both the type IB topoisomerases and the
tyrosine recombinases to regulate catalytic activity. These results
expand our understanding of the roles active-site flexibility play
in regulating DNA manipulation and metabolism.
Pourquier et al. (16) have shown that the presence of an
8-oxoG base at the scissile 1 position decreases DNA cleavage
by human topoisomerase I in single-turnover studies. We can
explain this observation based on our crystal structure. The
inactive docking of the catalytic residue away from the site of
catalysis, as well as disorder in the active site, are likely to slow
the DNA cleavage activity of the enzyme. The O8 atom of the
8-oxoG base also appears to clash sterically with Thr-718 in the
position this residue occupies in all of the previous human
topoisomerase I structures reported to date (Fig. 4A), forcing the
enzyme to favor its inactive conformation in the presence of an
8-oxoG base. The CAT and C-terminal regions change in
structure to accommodate the conformation of the Tyr-723–Phe
residue, which fits within an interior pocket and could be
stabilized by two hydrogen bonds (Figs. 3B and 4A). Thus, the
presence of the 8-oxoG base appears to limit the ability of human
topoisomerase I to assemble its active site before catalysis,
slowing the observed rate of DNA cleavage by the enzyme.
Pourquier et al. (16) also report that human topoisomerase I
has increased affinity for a DNA duplex containing 8-oxoG at
the scissile 1 position. We find that the Asn-722 side chain of
human topoisomerase I can be modeled to form a potential
hydrogen bond with the O8 atom of the 8-oxoG base (although
in the current structure this hydrogen bond is not made). It is
likely that at the DNA binding stage of the topoisomerase I
catalytic cycle Asn-722 hydrogen bonds with the DNA phosphate
backbone or with an 8-oxoG base in a damaged DNA molecule.
Mutagenesis studies support the importance of polar interac-
Fig. 5. Proposed mechanism for the initial stages of human topoisomerase
I activity. The enzyme’s inactive conformation contains a docked catalytic
tyrosine (Y in red), while its active conformation (Y in green) is ready for
catalysis.
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tions between the side chain immediately N-terminal to the
catalytic tyrosine and the DNA substrate. An Asn-726–His
mutation in Saccharomyces cerevisiae topoisomerase I (equiva-
lent to Asn-722 in the human enzyme) or Asn-722–His in human
topoisomerase I generate enzymes with increased equilibrium
cleavage activity relative to wild-type protein on nondamaged
DNA substrates (16, 31). The yeast Asn-726–His mutant topo-
isomerase I shows a further 5-fold increase in cleavage activity
in the presence of an 8-oxoG at the scissile 1 position (16).
Thus, the amino acid adjacent to the catalytic tyrosine in
topoisomerase I is likely to form critical interactions with the
DNA that enhance catalysis.
Based on our structural results, we propose the following
model for the initial stages of human topoisomerase I catalytic
activity (Fig. 5). Human topoisomerase I may exist in an inactive
conformation when not bound to DNA, with its catalytic Tyr-723
residue buried in a manner similar to that observed in the 8-oxoG
structure reported here. We suggest that upon binding duplex
DNA human topoisomerase I remains in the catalytically inac-
tive state with the active site Tyr-723 buried. Once the enzyme
has oriented itself in a productive manner on the DNA substrate,
a conformational change in the enzyme occurs in which the
catalytic tyrosine rotates away from its buried position, finalizing
the formation of the active site and facilitating the ordering of
Arg-590. This conformation of human topoisomerase I, seen in
many previously described structures, is the active state of the
enzyme that is capable of catalyzing the single-strand DNA
cleavage and formation of the 3 phosphotyrosine protein–DNA
intermediate. The O8 atom of 8-oxoG appears to inhibit the final
reorganization of the enzyme’s active site perhaps because of a
steric clash with Thr-718.
An alternative interpretation of our structural data is that
8-oxoG induces the formation of an inactive conformation of
human topoisomerase I that is not part of this enzyme’s normal
catalytic cycle. However, the conservation of the two potential
hydrogen bonding partners for Tyr-723 within the interior
binding pocket suggests that those residues may be important for
the enzyme’s action within the cell. A mutation of Ser-719, one
of these hydrogen bonding partners, to alanine would be useful
in examining the physiological relevance of these potential
interactions. If topoisomerase I only uses the interior binding
pocket in the presence of 8-oxoG lesion, one would expect that
a Ser-719–Ala mutation would have a greater impact on the
action of the enzyme on 8-oxoG-containing DNA substrates
than on nondamaged substrates.
It is likely the distortions within the DNA duplex caused by
other sites of DNA damage adjacent to the strand cleavage site
will cause similar structural impact on human topoisomerase I
and decrease catalytic activity. Indeed, several forms of DNA
damage, including etheno-adenine, Ara-C, uracil incorporation,
mismatches, and abasic sites (15, 20–22), inhibit human topo-
isomerase I. In summary, the type IB topoisomerases appear to
join the tyrosine recombinases in using docked catalytic ty-
rosines to regulate activity in the absence of ideal DNA sub-
strates. Further, it may be possible to exploit this inactive form
of human topoisomerase I in the development of novel thera-
peutics useful for treating human disease.
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